NasdaqGS:OVID

Stock Analysis Report

Executive Summary

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.

Rewards

Trading at 52.6% below its fair value

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year



Snowflake Analysis

Adequate balance sheet and slightly overvalued.

Share Price & News

How has Ovid Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OVID's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.0%

OVID

0.3%

US Biotechs

0.8%

US Market


1 Year Return

37.9%

OVID

14.5%

US Biotechs

17.8%

US Market

Return vs Industry: OVID exceeded the US Biotechs industry which returned 14.5% over the past year.

Return vs Market: OVID exceeded the US Market which returned 17.8% over the past year.


Shareholder returns

OVIDIndustryMarket
7 Day4.0%0.3%0.8%
30 Day68.0%8.7%1.8%
90 Day74.4%15.7%4.1%
1 Year37.9%37.9%15.6%14.5%20.4%17.8%
3 Yearn/a27.3%23.1%45.9%36.4%
5 Yearn/a7.5%2.3%68.1%49.6%

Price Volatility Vs. Market

How volatile is Ovid Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ovid Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OVID ($4.15) is trading below our estimate of fair value ($8.76)

Significantly Below Fair Value: OVID is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OVID is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OVID is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OVID's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OVID is overvalued based on its PB Ratio (5.2x) compared to the US Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Ovid Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

33.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OVID is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OVID is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OVID is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if OVID's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if OVID's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OVID's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Ovid Therapeutics performed over the past 5 years?

-26.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OVID is currently unprofitable.

Growing Profit Margin: OVID is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OVID is unprofitable, and losses have increased over the past 5 years at a rate of -26.6% per year.

Accelerating Growth: Unable to compare OVID's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OVID is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: OVID has a negative Return on Equity (-187.68%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Ovid Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: OVID's short term assets ($39.2M) exceed its short term liabilities ($10.4M).

Long Term Liabilities: OVID's short term assets ($39.2M) exceed its long term liabilities ($286.6K).


Debt to Equity History and Analysis

Debt Level: OVID is debt free.

Reducing Debt: OVID has not had any debt for past 5 years.


Balance Sheet

Inventory Level: OVID has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if OVID's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OVID has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OVID has less than a year of cash runway if free cash flow continues to reduce at historical rates of -34.3% each year


Next Steps

Dividend

What is Ovid Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate OVID's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OVID's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OVID's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OVID's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OVID's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Ovid Therapeutics's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Jeremy Levin (66yo)

4.8yrs

Tenure

US$2,661,538

Compensation

Dr. Jeremy Max Levin, BA Zoology, DPhil, MB BChir, has been the Chief Executive Officer of Ovid Therapeutics Inc. since March 2015 and serves as its Executive Director. From 1996 to 2000, Dr. Levin has mor ...


CEO Compensation Analysis

Compensation vs Market: Jeremy's total compensation ($USD2.66M) is above average for companies of similar size in the US market ($USD1.12M).

Compensation vs Earnings: Jeremy's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

0.8yrs

Average Tenure

54yo

Average Age

Experienced Management: OVID's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

3.7yrs

Average Tenure

64yo

Average Age

Experienced Board: OVID's board of directors are considered experienced (3.7 years average tenure).


Insider Trading

Insider Buying: OVID insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$1,568,52127 Nov 19
Shira Capital LLC
EntityCompany
Shares499,529
Max PriceUS$3.14
BuyUS$5,000,00022 Nov 19
Millennium Pharmaceuticals Inc., Asset Management Arm
EntityCompany
Shares2,000,000
Max PriceUS$2.50
BuyUS$150,00010 Oct 19
Jeremy Levin
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares60,000
Max PriceUS$2.50
SellUS$15,24807 Oct 19
Shira Capital LLC
EntityCompany
Shares5,543
Max PriceUS$2.75
BuyUS$2,12907 Oct 19
Tradelink Securities, LLC, Asset Management Arm
EntityCompany
Shares1,220
Max PriceUS$1.74
SellUS$27,70907 Oct 19
Tradelink Securities, LLC, Asset Management Arm
EntityCompany
Shares11,964
Max PriceUS$2.38
BuyUS$4,08201 Mar 19
Tradelink Securities, LLC, Asset Management Arm
EntityCompany
Shares329,426
Max PriceUS$2.65
BuyUS$001 Mar 19
Shira Capital LLC
EntityCompany
Shares2,000,000
Max PriceUS$2.00
SellUS$001 Mar 19
Shira Capital LLC
EntityCompany
Shares5,519
Max PriceUS$3.09
SellUS$2,21201 Mar 19
Tradelink Securities, LLC, Asset Management Arm
EntityCompany
Shares17,821
Max PriceUS$3.56
BuyUS$20,21001 Mar 19
Karen Bernstein
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$2.02
BuyUS$150,00027 Feb 19
Jeremy Levin
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares75,000
Max PriceUS$2.00

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.2%.


Management Team

  • Jeremy Levin (66yo)

    Chairman & CEO

    • Tenure: 4.8yrs
    • Compensation: US$2.66m
  • Matthew During (62yo)

    Founder & Chairman of Scientific Advisory Board

    • Tenure: 0.7yrs
    • Compensation: US$1.39m
  • Anna Kazanchyan (50yo)

    Senior Vice President of Product Development

    • Tenure: 0yrs
  • Dirk Haasner (54yo)

    Senior Vice President of Manufacturing & CMC QA

    • Tenure: 3.8yrs
    • Compensation: US$1.18m
  • Claude Nicaise (66yo)

    Head of Strategic Orphan Regulatory Affairs

    • Tenure: 0yrs
  • Tim Daly (48yo)

    Executive Vice President of Finance

    • Tenure: 0.08yrs
  • Lora Pike

    Senior Director of Investor Relations & Public Relations

    • Tenure: 0yrs
  • Amit Rakhit (49yo)

    President

    • Tenure: 0.08yrs
    • Compensation: US$1.55m
  • Suzanne Wakamoto

    Senior Vice President of Human Resources

    • Tenure: 0yrs
  • Tom Perone (54yo)

    Senior VP

    • Tenure: 0.8yrs

Board Members

  • Jeremy Levin (66yo)

    Chairman & CEO

    • Tenure: 4.8yrs
    • Compensation: US$2.66m
  • Doug Williams (61yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$101.07k
  • Barbara Duncan (54yo)

    Independent Director

    • Tenure: 2.5yrs
    • Compensation: US$91.07k
  • Bart Friedman (74yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$88.57k
  • Matthew During (62yo)

    Founder & Chairman of Scientific Advisory Board

    • Tenure: 0.7yrs
    • Compensation: US$1.39m
  • Jacqueline French

    Member of Scientific Advisory Board

    • Tenure: 2.9yrs
  • Howard Federoff

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Karen Bernstein (66yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$101.07k
  • Daniel Geschwind

    Member of Scientific Advisory Board

    • Tenure: 3.7yrs
  • David Eidelberg

    Member of the Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Ovid Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ovid Therapeutics Inc.
  • Ticker: OVID
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$198.438m
  • Shares outstanding: 47.82m
  • Website: https://www.ovidrx.com

Number of Employees


Location

  • Ovid Therapeutics Inc.
  • 1460 Broadway
  • Suite 15044
  • New York
  • New York
  • 10036
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OVIDNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2017
1OTDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2017

Biography

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candida ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/12 00:34
End of Day Share Price2019/12/11 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.